

AMENDMENT

A Version With Markings to Show Changes Made follows Applicant's Remarks.

In the Specification:

Please delete the paragraph at page 4, lines 6-11, and insert therefor the following:

F1 --Intracarotid infusion of leukotriene C₄ (LTC₄) selectively increases the permeability in brain tumor capillaries without affecting the permeability in normal brain capillaries. The effect of LTC₄ on brain tumor capillaries is, however, limited to small molecules and it can only slightly increase the permeability of those small molecules in abnormal brain tissue relative to normal. Accordingly, LTC₄ does not significantly increase the delivery of some larger water soluble molecules to brain tumors or other abnormalities.--.

[Please delete the paragraph at page 11, lines 4-11, and insert therefor the following:

F2 --However, the potassium channel agonist employed in the inventive methods is one other than the vasodilator bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg)(SEQ ID NO:1), or a polypeptide bradykinin analog, such as receptor mediated permeabilizer (RMP)-7 or A7 (e.g., Kozarich *et al.*, U.S. Patent No. 5,268,164 and PCT Application No. WO 92/18529). Other analogs of bradykinin include related peptide structures which exhibit the same properties as bradykinin but have modified amino acids or peptide extensions on either terminal end of the peptide. Examples of bradykinin analogs include [phe⁸ (CH₂-NH) Arg⁹-bradykinin, N-acetyl [phe⁸ (CH₂--NH--Arg⁹] bradykinin and desArg⁹-bradykinin.--.

34

8